Get the lastest analysis
Know what's happening as soon as it does. Benefit from our analysts' decades of insight and market projection experience to make your next move.Free
Posted in: Autologous, CAR-T, CD19 Mar 15 | 2024Obe-cel MAA Submitted to the EMA; Nucleus Manufacturing Facility Ready for Obe-cel Launch; Obe-cel’s Trial in SLE and AUTO6NG’s Study in Pediatric Glioblastoma Initiated; Autolus Q4 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 07 | 2024Yescarta Revenue Decreases while Tecartus Sales Hold; ZUMA-24 Readout Delayed to H2 2024; Anito-cel's Trial in Early Line MM to Initiate in H2 2024; Gilead’s Q4 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, TCR Feb 02 | 20242seventy bio to Focus Exclusively on Abecma; Sells Pipeline to Regeneron; Afami-Cel BLA Granted Priority ReviewAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jan 31 | 2024Breyanzi Regulatory Applications for R/R FL and R/R MCL Accepted in the US and JapanAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 26 | 2024CHMP Adopts Positive Opinion for Abecma in ≥3L MM; January CHMP HighlightsAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Jan 24 | 2024Sales of Carvykti Continue to Grow; FDA and EMA Advisory Committees Will Review Carvykti Applications for Early MM; JNJ Considers Entering in Autoimmune Diseases; JNJ’s Q4 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jan 22 | 2024Obe-cel BLA in R/R B-ALL Accepted Although No Priority Review Was GrantedAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19 Jan 11 | 2024JPM 2024 Analysis Day 3: AllogeneAccess Free Blast